GlaxoSmithKline CEO Emma Walmsley has reportedly received a pay cut of 14 per cent after the company missed an internal profit target for sales of routine vaccinations against other diseases.
According the pharmaceutical giant’s annual report, Ms Walmsley’s total remuneration for 2020 came in at seven million pounds (€8.2 million).
The cut, according to comments by Non-Executive Director Urs Rohner in the report, partly reflected a missed internal profit target for biopharmaceuticals, mainly due to lockdowns stopping people from receiving routine vaccinations which cut into the CEO’s bonus.
Ms Walmsley was appointed CEO in 2017, and has made great strides in the company’s restructuring efforts, as it works to split its consumer and pharmaceutical businesses.
GlaxoSmithKline has been among the frontrunners in the effort to develop COVID-19 vaccines and treatments, with the company’s offering, which was developed in conjunction with the University of Oxford, having been approved for use in over 50 countries.
Last month, pharmaceutical chiefs came under fire as EU leaders prioritised the acceleration of COVID-19 vaccination rollouts, with pharmaceutical companies being pressed to abide by delivery commitments.
Two masterpieces, one remarkable instrument
Michael Pantalleresco explores the poetry, passion and brilliance of the clarinet in works by Mozart and Weber.
‘A setting we couldn’t be prouder of’: db CEO on Hard Rock Hotel’s new rooftop restaurant
Cyana’s head chef is Spiros Tzilis, a Greek chef who has worked at Michelin-starred restaurants.
‘AI might be faster and cheaper, but at what cost?’ – Aramis Capital MD
He warns that businesses risk sacrificing service quality, human judgement and accountability in their pursuit of greater efficiency through artificial ...
‘We’re already late’: Employers chief calls for cross-party mass transport agreement
Through cross-party agreement, the solution will endure beyond individual legislatures, he explains.
